NCT06376058 Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section
| NCT ID | NCT06376058 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aretaieion University Hospital |
| Condition | Cesarean Section |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-01-10 |
| Primary Completion | 2026-01-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-01-10 with a primary completion date of 2026-01-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This will be a prospective randomized study, aiming at comparing an intrathecal fixed dose of chloroprocaine 1% versus an intrathecal fixed dose of ropivacaine 0.75% in elective cesarean sections
Eligibility Criteria
Inclusion Criteria: * adult parturients, American Society of Anesthesiologists (ASA) I-II, * singleton gestation\>37 weeks * elective cesarean section Exclusion Criteria: * American Society of Anesthesiologists (ASA) \> III * age \< 18 years * singleton gestation \<37 weeks * Body Mass Index (BMI) \>40 kg/m2 * Body weight \<50 kg * Body weight\>100 kg * height\<150 cm * height\>180 cm * multiple gestation * emergency delivery * fetal abnormality * fetal distress * pregnancy-induced pathology such as preeclampsia, eclampsia, premature labor, placental abnormalities * pregnancy- induced diseases such as hepatic failure, pseudocholinesterase deficiency, neuromuscular diseases * lack of informed consent * contraindication for regional anesthesia such as thrombocytopenia, coagulation abnormalities, allergy to local anesthetics
Contact & Investigator
Kassiani Theodoraki, PhD, DESA
PRINCIPAL INVESTIGATOR
Aretaieion University Hospital
Frequently Asked Questions
Who can join the NCT06376058 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 48 Years, studying Cesarean Section. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06376058 currently recruiting?
Yes, NCT06376058 is actively recruiting participants. Contact the research team at ktheodoraki@hotmail.com for enrollment information.
Where is the NCT06376058 trial being conducted?
This trial is being conducted at Athens, Greece.
Who is sponsoring the NCT06376058 clinical trial?
NCT06376058 is sponsored by Aretaieion University Hospital. The principal investigator is Kassiani Theodoraki, PhD, DESA at Aretaieion University Hospital. The trial plans to enroll 60 participants.